Inactive Instrument

tella, Inc. Stock

Equities

2191

JP3545900007

Biotechnology & Medical Research

Dynamic Chart
Tella, Inc.(JASDAQ:2191) dropped from S&P Global BMI Index CI
Beroni Group Signs Mou with tella, Inc. to Collaborate in Immunotherapy for Cancer Treatment CI
Argentina Tries to Tax and Spend Its Way Out of an Economic Crisis DJ
Cenegenics Japan Co., Ltd. completed the acquisition of 51% stake in Prometheus. Biotech Corporation. from tella, Inc.. CI
Cenegenics Japan Co., Ltd. agreed to acquire 51% stake in Prometheus. Biotech Corporation. from tella, Inc. for ¥153 million. CI
Tella, Inc. announced that it has received ¥1.0010013 billion in funding from Cenegenics Japan Co., Ltd. CI
Tella, Inc. announced that it expects to receive ¥1.0010013 billion in funding from Cenegenics Japan Co., Ltd. CI
Tella, Inc.(JASDAQ:2191) added to S&P Global BMI Index CI
Argentina defuses default crisis with 'massive' debt deal RE
Tella, Inc. acquired 51% stake in Prometheus Biotech Corporation from Cenegenics Japan Co., Ltd. for approximately ¥150 million. CI
Shogo Kozuka cancelled the acquisition of TITAN Inc. from tella, Inc. from tella, Inc.. CI
Now for the hard part: Argentina must fix economy after debt deal RE
Shogo Kozuka agreed to acquire TITAN Inc. from tella, Inc. from tella, Inc.. CI
Tella, Inc. announced that it has received ¥3.66 million in funding from Evolution Capital Management, LLC CI
Tella, Inc. announced that it expects to receive ¥3.54 million in funding from Evolution Capital Management, LLC CI
More news
Managers TitleAgeSince
President 33 22-03-28
Chief Administrative Officer - -
Members of the board TitleAgeSince
Director/Board Member 38 21-02-28
Director/Board Member 60 21-02-28
President 33 22-03-28
More insiders
tella, Inc. is a Japan-based company mainly engaged in the provision of techniques and operational knowhow associated with cell medicines, as well as the research and development of regenerative medicine and cell medicine. The Company operates through three business segments. The Cell Medicine segment is engaged in the provision of cancer treatment technology and operational method centered on dendritic cell vaccine therapy. This segment is also engaged in the provision of Services for contract medical institutions, such as cell culture system maintenance support services, management system maintenance support services and disease support services. The Medical Support segment is mainly engaged in the provision of drug development services (CROs) and genetic testing services. The Pharmaceutical segment is engaged in the development of the dendritic cell vaccine for regulatory approval as a product for cancer regenerative medicine.
More about the company